GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured.
GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early.
GRAIL was fouunded in 2015. The company is located in Menlo Park, California and Hong Kong.
GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer.
GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. GRAIL’s unique ability to sequence broadly across the genome allows us to discover the millions of unique patterns that define cancer.
GRAIL is backed by Ally Bridge Group, Hillhouse Capital Group, Sequoia Capital China, PSP Investments, CPP Investments, ICBC International, Blue Pool Capital and others. The company raised $390M in a Series D round on May 06, 2020. This new round brings GRAIL's total funding to $2.1B to date. GRAIL was reportedly valued at $3.2B in May 2018.